Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24539654 | 0.89 | TLR7 (0.80) | TLR7TLR8 | |
| SCHEMBL24539507 | 0.87 | TLR7 (1.00) | TLR7TLR8 | |
| SCHEMBL24538683 | 0.84 | TLR7 (1.00) | TLR7TLR8 | |
| SCHEMBL30586087 | 0.82 | TLR7 (0.70) | TLR7TLR8 | |
| SCHEMBL25255309 | 0.82 | TLR7 (0.70) | TLR7TLR8 | |
| SCHEMBL13837232 | 0.80 | TLR7 (1.00) | TLR7TLR8 | |
| SCHEMBL30577190 | 0.79 | TLR7 (1.00) | TLR7TLR8 | |
| SCHEMBL13837354 | 0.79 | TLR7 (1.00) | TLR7TLR8 | |
| SCHEMBL24539523 | 0.79 | TLR7 (1.00) | TLR7TLR8 | |
| SCHEMBL24539489 | 0.78 | TLR7 (1.00) | TLR7TLR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240124484-A1 | IMIDAZOTHIENOPYRIDINE COMPOUNDS AND METHODS OF USE | ZYMEWORKS BC INC (CA) | 2024-04-18 | — | — | US | disclosed |
| EP-4263553-A1 | IMIDAZOTHIENOPYRIDINE COMPOUNDS AND METHODS OF USE | Zymeworks BC Inc. (CA) | 2023-10-25 | — | — | EP | disclosed |
| WO-2023125121-A1 | TRICYCLIC COMPOUND, METHOD FOR PREPARING SAME, AND USE THEREOF | 四川科伦博泰生物医药股份有限公司 | 2023-07-06 | — | — | WO | disclosed |
| WO-2022126263-A1 | IMIDAZOTHIENOPYRIDINE COMPOUNDS AND METHODS OF USE | ZYMEWORKS INC. (CA) | 2022-06-23 | — | — | WO | disclosed |
| WO-2022126263-A1 | IMIDAZOTHIENOPYRIDINE COMPOUNDS AND METHODS OF USE | ZYMEWORKS INC. (CA) | 2022-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240124484-A1 | IMIDAZOTHIENOPYRIDINE COMPOUNDS AND METHODS OF USE | DHFR, RARS2, DPYD | TLR7 1139/4885TLR8 3109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.